Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders

Pharmacogenomics Journal

Volumn 2, Issue 4, 2002, Pages 217-235

  Hahn, M K ^a   Blakely, R D ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Dopamine; Norepinephrine; Polymorphism; Serotonin; SNP; Transporter

Indexed keywords

AMFEBUTAMONE; AMFONELIC ACID; AMOXAPINE; ANTIDEPRESSANT AGENT; CARRIER PROTEIN; CITALOPRAM; DESIPRAMINE; DOPAMINE TRANSPORTER; DOXEPIN; FLUVOXAMINE; LOFEPRAMINE; MAPROTILINE; MAZINDOL; METHYLPHENIDATE; MONOAMINE TRANSPORTER; NEUROTRANSMITTER; NOMIFENSINE; NORADRENALIN TRANSPORTER; NORCLOMIPRAMINE; NORTRIPTYLINE; OXAPROTILINE; PAROXETINE; PINDOLOL; PROTRIPTYLINE; REBOXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR; DRUG DEPENDENCE; DRUG RESPONSE; DRUG TARGETING; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; IMPULSIVENESS; INDIVIDUALITY; MARKER GENE; MENTAL DISEASE; NEUROTRANSMISSION; NUCLEOTIDE SEQUENCE; OBSESSION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGY; PERSONALITY DISORDER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; SUICIDE; UNINDEXED SEQUENCE;

BIOGENIC MONOAMINES; CARRIER PROTEINS; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0036046157     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500106     Document Type: Review

References (206)

1. The catecholamine hypothesis of affective disorders: A review of supporting evidence
2. Role of norepinephrine in the pathophysiology and treatment of mood disorders
3. The role of noradrenaline in depression: A review
4. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression
5. Evidence for reduction of norepinephrine uptake sites in the failing human heart
6. Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation
7. Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy
8. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy
9. Norepinephrine kinetics in essential hypertension. Defective neuronal uptake of norepinephrine in some patients
10. Activation of histamine H3-receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia. Comparison with adenosine A1 -receptors and alpha2-adrenoceptors
11. Neuroscience of addiction
12. Perspectives on the discovery of central monoaminergic neurotransmission
13. The Dopamine Transporter. Potential involvement in neuropsychiatric disorders
14. Central serotonin and impulsive aggression
15. Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter
16. 5-HT and alcohol abuse
17. Platelets 3H 5-HT uptake in descendants from alcoholic patients: A potential risk factor for alcohol dependence?
18. Norepinephrine and serotonin transporters: Molecular targets of antidepressant drugs
19. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
20. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants
21. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice
22. Neurotransmitter transporters: Recent progress
23. Human norepinephrine transporter. Biosynthetic studies using a site-directed polyclonal antibody
24. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition
25. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants
26. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A
27. Acute regulation of norepinephrine transport: I. Protein kinase C- linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells
28. Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins
29. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes
30. Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein
31. Assignment of the norepinephrine transporter protein (NET1) locus to chromosome 16
32. Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter
33. Molecular cloning and organization of the coding region of the human norepinephrine transporter gene
34. A previously undescribed intron and extensive 5′ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene
35. Cloning and functional characterization of the human norepinephrine transporter gene promoter
36. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR
37. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter
38. Human dopamine transporter gene: Coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations
39. Structure and organization of the gene encoding human dopamine transporter
40. Human and mouse dopamine transporter genes: Conservation of 5′-flanking sequence elements and gene structures
41. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene
42. Linkage mapping of serotonin transporter protein gene SLC6A4 on chromosome 17
43. Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization
44. Gene organization and polymorphisms of monoamine transporters. Relationship to psychiatric and other complex diseases
45. The human noradrenaline transporter gene contains multiple polyadenylation sites and two alternatively spliced C-terminal exons
46. Functional characterization of the splicing variants of human norepinephrine transporter
47. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1
48. Alternative splicing of the human serotonin transporter gene
49. Inherited sodium channelopathies, novel therapeutic and proarrhythmic molecular mechanisms
50. Beta(2)-adrenergic receptor pharmacogenetics
51. Down-regulation of the human norepinephrine transporter in intact 293- hNET cells exposed to desipramine
52. Regulation of gamma-aminobutyric acid (GABA) transporters by extracellular GABA
53. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression
54. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters
55. Relationship between subjective effects of cocaine and dopamine transporter occupancy
56. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers
57. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET
58. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
59. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses
60. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression
61. Can recovery from depression be achieved?
62. TaqI RFLP at norepinephrine transporter protein (NET) locus
63. Manic-depression and the norepinephrine transporter gene
64. Systematic search for variation in the human norepinephrine transporter gene: Identification of five naturally occurring missense mutations and study of association with major psychiatric disorders
65. Tourette syndrome and the norepinephrine transporter gene: Results of a systematic mutation screening
66. Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression
67. Pharmacological properties of naturally occurring variants of the human norepinephrine transporter
68. Patterns of single nucleotide polymorphisms in candidate genes for blood-pressure homeostasis
69. Role of human norepinephrine transporter gene single nucleotide polymorphisms in cardiovascular disease
70. The epidemic of orthostatic tachycardia and orthostatic intolerance
71. Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance
72. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine
73. Clues to the origin of orthostatic intolerance: A genetic defect in the cocaine- and antidepressant sensitive norepinephrine transporter
74. Oligomerization of serotonin transporter and its functional consequences
75. Symmetrical climer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment
76. Physiological genomics of antidepressant targets: Keeping the periphery in mind
77. A 40-nucleoticle repeat polymorphism in the human dopamine transporter gene
78. Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 cloparnine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor ciliary neurotrophic factor (CNTF))
79. Global variation of a 40-bp VNTR in the 3′-untranslated region of the dopamine transporter gene (SLC6A3)
80. Distribution of the 3′ VNTR polymorphism in the human dopamine transporter gene in world populations
81. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic Taql RFLPs
82. VNTR polymorphism for the human dopamine transporter gene (DAT1)
83. Characterization of single-nucleotide polymorphisms in coding regions of human genes
84. Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1)
85. Identification of a novel polymorphism of the human dopamine transporter (DAT1) gene and the significant association with alcoholism
86. A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease
87. Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder
88. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia
89. Dopamine transporter gene polymorphisms are not associated with polysubstance abuse
90. Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium
91. Modification of alcohol withdrawal by the A9 allele of the dopamine transporter gene
92. Variation of the genes encoding the human glutamate EAAT2, serotonin and dopamine transporters and susceptibility to idiopathic generalized epilepsy
93. DAT1 gene polymorphism in alcoholism: A family-based association study
94. Genotype influences in vivo dopamine transporter availability in human striatum
95. Dopamine transporter gene polymorphism and alcoholism
96. Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders
97. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways
98. Linkage disequilibrium between the dopamine transporter gene (DAT1) and bipolar disorder: Extending the transmission disequilibrium test (TDT) to examine genetic heterogeneity
99. Possible locus for bipolar disorder near the dopamine transporter on chromosome 5
100. Family-based association studies of bipolar disorder with candidate genes involved in dopamine neurotransmission: DBH, DAT1, COMT, DRD2, DRD3 and DRD5
101. Dopamine genes and ADHD
102. Dopamine transporter density in patients with attention deficit hyperactivity disorder
103. Attention deficit hyperactivity disorder: Binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment
104. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography
105. Association of attention-deficit disorder and the dopamine transporter gene
106. Mapping susceptibility loci in attention deficit hyperactivity disorder: Preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children
107. Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples
108. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism
109. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: Heterogeneity owing to diagnostic subtype and severity
110. A family-based and case-control association study of the dopamine D4 receptor gene and dopamine transporter gene in attention deficit hyperactivity disorder
111. Attention-deficit hyperactivity disorder: A study of association with both the dopamine transporter gene and the dopamine D4 receptor gene
112. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response
113. Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder
114. Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson's disease: No association found
115. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease
116. Isoform-specific 3′-untranslated sequences sort alpha-cardiac and beta-cytoplasmic actin messenger RNAs to different cytoplasmic compartments
117. The influence of the base-paired flanking region on structure and function of the ferritin mRNA iron regulatory element
118. Multiple elements in the c-fos protein-coding region facilitate mRNA deadenylation and decay by a mechanism coupled to translation
119. The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons
120. Prediction of dopamine transporter binding availability by genotype: A preliminary report
121. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans
122. Dopamine transporters increase in human brain after alcohol withdrawal
123. Pstl RFLP at the SERT locus
124. Allelic variation of human serotonin transporter gene expression
125. A novel allelic variant of the human serotonin transporter gene regulatory polymorphism
126. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects
127. Population studies of polymorphisms of the serotonin transporter protein gene
128. Serotonin transporter gene polymorphisms: Ethnic difference and possible association with bipolar affective disorder
129. A novel allele in the promoter region of the human serotonin transporter gene
130. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants
131. The human serotonin transporter gene polymorphism-basic research and clinical implications
132. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region
133. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets
134. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension
135. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism
136. Organization of the human serotonin transporter gene
137. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo
138. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells
139. Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells
140. Modified structure of the human serotonin transporter promoter
141. Mosaicism for a serotonin transporter gene promoter-associated deletion: Decreased recombination in depression
142. Primary structure of the serotonin transporter in unipolar depression and bipolar disorder
143. Presence of multiple functional polyadenylation signals and a single nucleotide polymorphism in the 3′ untranslated region of the human serotonin transporter gene
144. Screening a large reference sample to identify very low frequency sequence variants: Comparisons between two genes
145. Serotonin transporter gene regulatory region polymorphism and anxiety-related traits in the Japanese
146. The serotonin transporter gene and peer-rated neuroticism
147. Neuroticism and polymorphisms in the serotonin transporter gene
148. No association between the serotonin transporter gene regulatory region polymorphism and the Tridimensional Personality Questionnaire (TPQ) temperament of harm avoidance
149. Neuroticism is not associated with the serotonin transporter (5-HTTLPR) polymorphism
150. An association study of a functional polymorphism of the serotonin transporter gene with personality and psychiatric symptoms
151. Association and linkage of anxiety-related traits with a functional polymorphism of the serotonin transporter gene regulatory region in Israeli sibling pairs
152. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample
153. The serotonin transporter gene and affective disorder
154. Polymorphism in serotonin transporter gene associated with susceptibility to major depression
155. Serotonin transporter gene polymorphism and affective disorder
156. Serotonin transporter (5-HTT) gene polymorphisms are not associated with susceptibility to mood disorders
157. Association analysis of 5HT transporter gene in bipolar disorder in the Indian population
158. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder
159. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders
160. Serotonin transporter (5-HTT) gene and bipolar affective disorder
161. Lack of linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and bipolar disorder
162. Multimarker haplotypes within the serotonin transporter gene suggest evidence of an association with bipolar disorder
163. A novel functional polymorphism within the promoter of the serotonin transporter gene: Possible role in susceptibility to affective disorders
164. Variability in the serotonin transporter gene and increased risk for major depression with melancholia
165. Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder
166. Seroton in-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression
167. Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders
168. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamin
169. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene
170. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-httlpr in delusional and nondelusional depression
171. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression
172. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: Preliminary findings
173. Serotonin transporter gene polymorphisms, alcoholism, and suicidal behavior
174. Analysis of catechol-O-methyltransferase and 5-hydroxytryptamine transporter polymorphisms in patients at risk for suicide
175. Suicide and the serotonin transporter gene
176. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide
177. Association of short alleles of a VNTR of the serotonin transporter gene with anxiety symptoms in patients presenting after deliberate self harm
178. Does the short variant of the serotonin transporter linked polymorphic region constitute a marker of alcohol dependence?
179. Serotonin transporter gene polymorphisms in alcohol dependence
180. Association analysis of a regulatory variation of the serotonin transporter gene with severe alcohol dependence
181. Association study of serotonin transporter gene regulatory region polymorphism and alcoholism
182. Selective genotyping for the role of 5-HT2A, 5-HT2C, and GABA alpha 6 receptors and the serotonin transporter in the level of response to alcohol: A pilot study
183. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels
184. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity
185. Neurogenetic adaptive mechanisms in alcoholism
186. Serotonin transporter gene variants in alcohol-dependent subjects with dissocial personality disorder
187. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior
188. Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity
189. Possible association of the short allele of the serotonin transporter promoter gene polymorphism (5-HTTLPR) with violent suicide
190. Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene
191. 5-HTTLPR variants not associated with autistic spectrum disorders
192. Evidence of linkage between the serotonin transporter and autistic disorder
193. Serotonin transporter (5-HTT) gene variants associated with autism?
194. Evidence for an association with the serotonin transporter promoter region polymorphism and autism
195. Role of the serotonin transporter gene in the behavioral expression of autism
196. A genomewide screen for autism: Strong evidence for linkage to chromosomes 2q, 7q, and 16p
197. A catalogue of imprinted genes and parent-of-origin effects in humans and animals
198. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder
199. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder
200. Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder
201. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene
202. Intact coding region of the serotonin transporter gene in obsessive-compulsive disorder
203. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder
204. The human dopamine transporter gene: The 5′-flanking region reveals five diallelic polymorphic sites in a Caucasian population sample